Treating PD-1/PD-L1 refractory MCC
1 Views
administrator
07/17/23
Paul Nghiem, MD, PhD, University of Washington, Seattle, WA, outlines ongoing trials for the treatment of refractory merkel cell carcinoma (MCC), including a Phase I/II trial of T-cell therapy of transgenic T-cell receptors (NCT03747484) and a trial of domatinostat. This interview took place during the 10th World Congress of Melanoma in conjunction with the 17th EADO Congress Interactive Virtual Meeting.
-
Category
Show more
Facebook Comments
No comments found